Looking at sales and split by region and what that might tell us...

Looking at sales and split by region and what that might tell us ? :-

EU $2,632k 2023 vs $ 355K 2022 This looks like engineering services and sales to AZ and the large UK clinical trials grant. ADR still highly dependant on AZ for majority revenue through engineering and clinical vs commercial. This was something they have said multiple times their strategy was to move away from. Some work to be done here to more to commercial sustainability.

US $536K 2023 vs $167k 2022, US revenue up by £369k some progress, a long way to go the break even again mentioned as 80,000 patients. A breakdown of this and which partner is delivering this and customer feedback would have been invaluable.

Its still a mystery why they are not transparent about the sales breakdown or progress towards the 80,000 patient target. If they were transparent about that it would give way more credability and confidence in the Leadership.